Week of May 31, 2026 — regulatory, research, and what readers asked

This week’s digest gathers what changed in the regulatory record, what landed in the indexed literature, and what readers are asking. Sources are linked inline; every claim should be traceable.

Regulatory desk

List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act

federal_register · 2026-05-01

The Food and Drug Administration (FDA, the Agency, or we) is evaluating substances that have been nominated for inclusion on a list of bulk drug substances (active pharmaceutical ingredients) for which there is a clinical need for outsourcing facilities to use in compounding (the 503B Bulks List). This notice identifies three bulk drug substances that FDA has considered and proposes not to include on the 503B Bulks List: semaglutide, tirzepatide, and liraglutide. Additional bulk drug substances

Source ↗

Advisory Committee; Psychopharmacologic Drugs Advisory Committee; Renewal

federal_register · 2026-05-29

The Food and Drug Administration (FDA) is announcing the renewal of the Psychopharmacologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Psychopharmacologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the June 4, 2028, expiration date.

Source ↗

Advisory Committee; Pulmonary-Allergy Drugs Advisory Committee; Renewal

federal_register · 2026-05-26

The Food and Drug Administration (FDA) is announcing the renewal of the Pulmonary-Allergy Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Pulmonary- Allergy Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 30, 2028, expiration date.

Source ↗

Advisory Committee; Drug Safety and Risk Management Advisory Committee; Renewal

federal_register · 2026-05-26

The Food and Drug Administration (FDA) is announcing the renewal of the Drug Safety and Risk Management Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Drug Safety and Risk Management Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 31, 2028, expiration date.

Source ↗

What readers are asking

Topics we’ll be tracking:

This is a draft assembled automatically from our data pipelines. It is not published until reviewed.